Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Phase 2 Study to Investigate the Efficacy and Safety of Zelicapavir in Participants Aged ≥28 Days to ≤36 Months of Age Infected With Respiratory Syncytial Virus
Sponsor: Enanta Pharmaceuticals, Inc
Summary
Zelicapavir is a novel, orally administered, nonfusion replication inhibitor of RSV. It is being investigated in this Phase 2 study (EDP 938-203) as a potential treatment for RSV infection in both hospitalized and non-hospitalized children aged ≥28 days to ≤36 months who present with symptomatic RSV infection.
Official title: Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Zelicapavir in Participants ≥28 Days to ≤36 Months of Age Infected With Respiratory Syncytial Virus
Key Details
Gender
All
Age Range
28 Days - 36 Months
Study Type
INTERVENTIONAL
Enrollment
150
Start Date
2026-07
Completion Date
2026-12
Last Updated
2026-07-10
Healthy Volunteers
No
Interventions
zelicapavir
Oral suspension
Placebo
Placebo oral suspension to match zelicapavir
Locations (8)
Center of Excellence for Pediatric Infectious Diseases and Vaccines Faculty of Medicine, Chulalongkorn University (CE-PID)
Bangkok, Thailand
Nakornping Hospital
Chiang Mai, Thailand
Maharaj Nakorn Chiang Mai Hospital
Chiang Mai, Thailand
Chiangrai Prachanukroh Hospital
Chiang Rai, Thailand
Khon Kaen Hospital
Khon Kaen, Thailand
Lampang Hospital
Lampang, Thailand
Lamphun Hospital
Lamphun, Thailand
Maha Sarakham Hospital
Maha Sarakham, Thailand